NAGE News & Events

Niagen Bioscience announced the sale of its ChromaDex Reference Standards business to LGC, as of February 24, in an all-cash transaction. The company said, "The divestiture further streamlines Niagen Bioscience's operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry."

Niagen Bioscience announced the broadening of its NAD+ precursor intellectual property portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside and derivatives in intravenous and injectable formulations.

Niagen Bioscience announced it has partnered with Truemed to allow qualified customers to purchase Tru Niagen using health savings account and flexible spending account funds on its website. Customers can use these funds with a Truemed letter of medical necessity issued by a licensed provider. "Truemed exists to make preventive health tools more financially accessible," said Justin Mares, co-founder and CEO of Truemed. "We are excited to help qualified customers use HSA/FSA funds to support their healthspan with Tru Niagen."

Niagen Bioscience announced that it has acquired a portfolio of existing patents covering nicotinamide riboside and its salt forms from Queen's University Belfast. The acquired portfolio comprises the core body of patents underpinning the production, composition, and commercial use of NR, encompassing foundational composition-of-matter patents covering crystal morphologies, methods of making NR and other NAD+ precursors, and global patent rights spanning multiple jurisdictions. Prior to this transaction, Niagen Bioscience previously held exclusive rights to these patents through long-standing licensing and joint ownership arrangements with QUB. With this acquisition, Niagen Bioscience now becomes the sole owner of this IP portfolio.